AgingBIOANCIENTNCT07707297
BIOANCIENT: Cohort of Centenarians in Navarra (1926-1927)
An observational study of Aging and Cellular Senescence, run by Fundacion Miguel Servet at 1 site in Spain.
Trial summary
Demographic aging is a growing global challenge, driven by increasing life expectancy and declining birth rates, with projections indicating that more than 30% of the European population will be over 65 years old by 2100. Read more about this study
- Who is it for?
- Ages 100 years and older
- Conditions the study is for
- Aging, Cellular Senescence, Biomarkers / Blood
- How many people
- 333 participants
- Where
- 1 siteSpain
- Study dates
- 4 Feb 2026to 31 Dec 2027
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 100 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: The study population consists of very old adults aged 100 years and older residing in Navarre, Spain. Participants will be community-dwelling or institutionalized individuals who meet the inclusion criteria and are able to undergo a comprehensive geriatric assessment. The study aims to include a representative sample of the centenarian population in the region.
Who may be able to join
- Individuals aged ≥100 years
- Residents of Navarre, Spain
Who cannot join
- Clinical decompensation within the last month, including hemodynamic instability, acute illness, or hospitalization;
- End-of-life condition, defined as a clinical state of irreversible deterioration with a life expectancy of days to weeks, as determined by a physician.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Navarrabiomed
Pamplona, Navarre, 31001
Fabíola Zambom Ferraresi, PhD, +34 848422521, fabiola.zambom.ferraresi@navarra.es
Icíar Echeverría Beistegui, PhD, +34 848 421 614, iechevbe@navarra.es
About this study
Demographic aging is a growing global challenge, driven by increasing life expectancy and declining birth rates, with projections indicating that more than 30% of the European population will be over 65 years old by 2100. Centenarians represent a unique biological model of extreme longevity, often exhibiting delayed onset of age-related diseases and preserved functional capacity.
This study aims to establish an intergenerational cohort of centenarians in Navarra (Spain) to investigate the biological, clinical, environmental, and lifestyle factors associated with extreme longevity. By integrating multidimensional data-including clinical assessments, functional and cognitive measures, and biological markers-this study seeks to improve understanding of aging mechanisms and identify potential determinants of healthy aging.
Read the detailed description
Demographic aging is a phenomenon with increasing structural impact, driven by rising life expectancy and declining birth rates. According to projections by Eurostat and the WHO, by 2050 more than 30% of the European population will be over 65 years old, posing significant challenges for the sustainability of healthcare and social systems, and requiring the development of specific strategies that integrate knowledge from geroscience, biotechnology, and artificial intelligence applied to health.
Navarre has privileged conditions for research into healthy aging, given its high rate of centenarians (44.09 per 100,000 inhabitants) and its high-level healthcare and scientific infrastructure. These strengths make the region an ideal environment for designing and implementing innovative strategies aimed at improving the health and quality of life of older adults, contributing to the sustainability of the healthcare system.
Centenarians constitute a particularly valuable biological model, as they reach advanced ages with relatively preserved functionality, suggesting the presence of protective mechanisms that remain incompletely understood. Contemporary geroscience adopts a holistic approach, emphasizing the interaction between genetic factors (such as longevity-associated alleles), epigenetic mechanisms (including DNA methylation), and environmental influences (including diet, physical activity, and living conditions) in shaping aging trajectories.
Multifactorial approaches have been increasingly applied to the study of centenarian cohorts, integrating clinical data with biomarkers of aging. Studies such as the Okinawa Centenarian Study have demonstrated associations between longevity and lifestyle factors including diet, physical activity, and social support, whereas the New England Centenarian Study has highlighted the contribution of genetic factors to extreme longevity and delayed onset of cardiovascular disease. European cohorts have similarly identified favorable metabolic profiles and delayed development of chronic conditions, often with a relevant hereditary component.
The present study aims to integrate multiple domains of knowledge in order to deepen the understanding of the biological mechanisms underlying longevity, reduce diagnostic barriers, optimize therapeutic strategies and healthcare resource utilization, and ultimately improve the quality of life of older adults.
- Conditions
- Aging, Cellular Senescence, Biomarkers / Blood, Age-Related Diseases, Frailty
- Keywords
- Centenarians, Healthy aging, Senescence, Geroscience, Age-related diseases, Longevity, Senescence biomarkers, Personalized medicine, Preventive medicine, Artificial intelligence in healthcare, Omics technologies (genomics, proteomics, metabolomics)
- Medical subject headings
- Frailty
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Centenarians resident in Navarre - Spain | Centenarians (individuals aged ≥100 years) residing in Navarre, Spain. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Integrated biological aging profile based on clinical and multi-omics biomarkers.
Clinical, funtional and molecular characterization of centenarian individuals using multi-omics biomarkers
Measured: Baseline and 1-year follow-up
Secondary outcomes (37)
Cognitive Function assessed with Mini Mental State Examination (MMSE)
Cognitive Function assessed with Mini-Mental State Examination (MMSE) is a 30-point tool designed to assess global cognitive function and screen for cognitive impairment, particularly in older adults. It evaluates several core areas of cognitive functioning, with higher scores indicating better cognitive performance, i.e. 30 (best) and 0 (worst).
The 11 tasks in the MMSE are generally categorized into the following areas of cognitive functioning: Orientation (10 points), Registration (3 points), Attention and Calculation (5 points); Recall (3 points): .Language and Praxis (9 points).
Measured: Baseline and 1-year follow-up
Functional status measured with Barthel Index
Barthel Index of independence during activities of daily living (ADLs) ranges from 0 (severe functional dependence) to 100 (functional independence).
Measured: Baseline and 1-year follow-up
Physical function assessed by Short Physical Performance Battery (SPPB)
Physical Function: Assessed using the Short Physical Performance Battery (SPPB), which combines balance, gait velocity, and leg strength as a single score on a 0 (worst) to 12 (best scale).
Measured: Baseline and 1-year follow-up
Frailty assessed by Fried Frailty Phenotype
The Fried Frailty Phenotype is a widely used clinical tool that defines frailty as a distinct syndrome in older adults, based on five key physical markers: unintentional weight loss, self-reported exhaustion, low physical activity, weak grip strength, and slow walking speed. It identifies individuals as frail if they meet 3 or more criteria, and pre-frail if they meet 1-2. Namely, 0 (best) and 5 (worst).
Measured: Baseline and 1-year follow-up
Lawton Instrumental Activities of Daily Living (IADL)
The Lawton Instrumental Activities of Daily Living (IADL) scale is a tool used to evaluate older adult's ability to perform complex, daily tasks necessary for independent community living. It focuses on eight functional domains, typically scoring 0-8 to indicate independence levels. Scale range of 0 (worst) to 8 (best).
Measured: Baseline and 1-year follow-up
Nutritional Status assessed using the Mini Nutritional Assessment - Short Form (MNA-SF)
Nutritional Status assessed using the Mini Nutritional Assessment - Short Form (MNA-SF), a rapid, validated 6-item screening tool designed to identify older adults (aged 65+) who are malnourished or at risk of malnutrition. It is widely used in hospitals, nursing homes, and community settings to initiate early nutritional interventions. Scoring from14 points (better) and 0 points (worse):12-14 points: Normal nutritional status; 8-11 points: At risk of malnutrition and; 0-7 points: Malnourished.
Measured: Baseline and 1-year follow-up
Hand Grip Strength
Muscle Strength assessed by handgrip strength using a dynamometer (Takey Physical Fitness Test) measured in kilograms. The minimum recorded measurement is 5 kg and the maximum is 100 kg. Grip strength is a powerful biomarker of aging and overall muscle strength. Low handgrip strength is associated with increased risks of cardiovascular disease, stroke, type 2 diabetes, and premature mortality.
Measured: Baseline and 1-year follow-up
Lower Limb Muscle Strength
Lower Limb Muscle Strength. Isometric lower limb muscle strength assessed using a Hoggan dynamometer. Knee extensor strength and hip flexor strength will be measured with participants in a standardized seated position, starting with the knee flexed (90º). Force will be recorded in kilograms (kg). Higher values indicate greater muscle strength.
Measured: Baseline and 1-year follow-up
Sarcopenia Risk (SARC-F questionnaire)
Risk of sarcopenia assessed using the SARC-F questionnaire, a five-item self-reported screening tool evaluating strength, assistance in walking, rising from a chair, climbing stairs, and falls. Total scores range from 0 to 10, with higher scores indicating greater risk of sarcopenia and functional decline.
Measured: Baseline and 1-year follow-up
Cognitive Function (Clock Drawing Test)
Cognitive function assessed using the Clock Drawing Test (CDT), in which participants are asked to draw a clock showing a specified time. The test evaluates executive function, visuospatial ability, and planning. Performance will be scored using a standardized scoring system, with higher scores indicating better cognitive performance. Results range from 0 (worst) to 10 (best).
Measured: Baseline and 1-year follow-up
Depressive Symptoms (Geriatric Depression Scale - GDS-15)
Depressive symptoms assessed using the Geriatric Depression Scale (GDS-15), a 15-item self-reported questionnaire designed to screen for depression in older adults. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms. Scores of 0-4 are considered normal, 5-9 suggest mild depression, and 10-15 indicate moderate to severe depression.
Measured: Baseline and 1-year follow-up
Health-Related Quality of Life (EQ-5D-5L)
Health-related quality of life assessed using the EQ-5D-5L instrument, which includes five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with five levels of severity, and a visual analogue scale (EQ VAS). The EQ-5D-5L index value typically ranges from values below 0 (health states worse than death) to 1 (full health), depending on the country-specific value set. The EQ VAS ranges from 0 (worst imaginable health) to 100 (best imaginable health). Higher scores indicate better health status.
Measured: Baseline and 1-year follow-up
Life Satisfaction (Satisfaction With Life Scale - SWLS)
Life satisfaction assessed using the Satisfaction With Life Scale (SWLS), a 5-item self-reported questionnaire developed by Diener et al. to evaluate global cognitive judgments of one's life satisfaction. Each item is rated on a 7-point Likert scale. Total scores range from 5 to 35, with higher scores indicating greater life satisfaction. Scores of 5-9 indicate extreme dissatisfaction, 10-14 dissatisfaction, 15-19 slightly below average, 20-24 average satisfaction, 25-29 high satisfaction, and 30-35 very high satisfaction.
Measured: Baseline and 1-year follow-up
Comorbidity Burden
Comorbidity burden assessed using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G), which evaluates the severity of chronic medical conditions across 14 organ systems. Each system is rated on a 5-point scale (0 = no problem to 4 = extremely severe impairment). The total score ranges from 0 to 56, with higher scores indicating greater comorbidity burden.
Measured: Baseline and 1-year follow-up
Proteomic Biomarkers
Proteomic biomarkers assessed through the identification and quantification of circulating proteins associated with aging and frailty using high-throughput proteomic techniques. Protein expression levels will be measured in biological samples (e.g., plasma or serum), and relative or absolute concentrations will be analyzed.
Measured: Baseline (single assessment)
Mobility and Functional Performance (Timed Up and Go Test - TUG)
Mobility and functional performance assessed using the Timed Up and Go (TUG) test. Participants are instructed to stand up from a standard chair, walk a distance of 3 meters, turn around, walk back to the chair, and sit down. The total time to complete the task is recorded in seconds. Lower times indicate better mobility and functional performance. Times greater than or equal to 12 seconds are commonly associated with increased risk of falls in older adults.
Measured: Baseline and 1-year follow-up
Polypharmacy
Polypharmacy assessed as the concurrent use of multiple medications. The total number of regularly prescribed medications will be recorded for each participant. Polypharmacy will be defined as the use of five or more medications (≥5). The outcome will be analyzed both as a continuous variable (number of medications) and as a categorical variable (presence vs absence of polypharmacy). Higher values indicate greater medication burden.
Prior and Concomitant Medication History; Baseline assessment of chronic pharmacological exposure. Participants report lifetime use (lasting >1 year) of 27 key drug classes (Yes/No), including cardiovascular, endocrine, respiratory, analgesic, anti-infective, neuropsychiatric, gastrointestinal, bone, and immune therapies. Long-term historical medications are also captured via open text. Reported as counts and percentages.
Measured: Baseline and 1-year follow-up
Bioimpedance Analysis (BIVA - Bioelectrical Impedance Vector Analysis)
Bioimpedance Analysis (BIVA - Bioelectrical Impedance Vector Analysis): Whole-body bioelectrical impedance vector analysis (BIVA) assessed using a phase-sensitive bioimpedance device (e.g., BIVA Pro). Raw bioelectrical parameters including resistance (R, ohms) and reactance (Xc, ohms) will be measured at 50 kHz and normalized by height (R/H, Xc/H).
BIVA provides a qualitative and semi-quantitative assessment of body composition, including hydration status and body cell mass, without relying on predictive equations. Vector displacement patterns will be interpreted as follows:
Vector shortening (↓R/H, ↓Xc/H): fluid overload or increased hydration Vector lengthening (↑R/H, ↑Xc/H): dehydration or reduced fluid content Increased phase angle: better cellular integrity and nutritional status Decreased phase angle: impaired cellular health or frailty
Measured: Baseline and 1-year follow-up
Falls (Number of falls over the past 12 months)
Total number of unintentional falls experienced by the participant during the 12 months prior to the assessment. A fall is defined as an unexpected event in which the participant comes to rest on the ground, floor, or lower level. Data will be collected via self-report calendar.
Measured: Baseline and 1-year follow-up
Fear of Falling
Assessment of the participant's fear of falling, categorized as a dichotomous outcome (Yes or No). Participants are asked the single standard question: "Are you afraid of falling?". A response of "Yes" indicates the presence of fear, while "No" indicates its absence.
Measured: Baseline and 1-year follow-up
Pain Intensity
Pain intensity will be assessed using a standard Visual Analog Scale (VAS). The scale consists of a 10 cm horizontal line, where the left endpoint (0) represents "no pain" and the right endpoint (10) represents "worst imaginable pain". Participants mark the point on the line that best represents their current pain level. Higher scores indicate greater pain severity.
Measured: Baseline and 1-year follow-up
Shoulder Mobility (External Rotation and Abduction and; Internal Rotation and Adduction)
Assessment of shoulder external rotation and abduction flexibility using a simplified functional reach test. Participants are asked to place the palm of their hand flat on the back of their neck (nuca). The outcome is categorized as a dichotomous variable: "Successful" if the participant can touch the back of the neck with the palm without compensatory movements, or "Unsuccessful" if they are unable to complete the movement. Both shoulders will be evaluated separately.
Assessment of shoulder internal rotation and adduction flexibility using a simplified functional reach test. Participants are asked to place the back of their hand (dorso) on their lower back, specifically above the sacrum. The outcome is categorized as a dichotomous variable: "Successful" if the participant can touch the area above the sacrum with the back of the hand without compensatory movements, or "Unsuccessful" if they are unable to complete the movement. Both shoulders will be evaluated separately.
Measured: Baseline and 1-year follow-up
Adherence to the Mediterranean Diet Measured by the MEDAS Score
Adherence to the Mediterranean diet will be assessed using the 14-item Mediterranean Diet Adherence Screener (MEDAS). The questionnaire evaluates the frequency of consumption of traditional Mediterranean food groups (such as olive oil, nuts, fruits, vegetables, and fish) and negative items (such as sugar-sweetened beverages and commercial sweets). Each of the 14 items is scored as 0 (does not meet the criteria) or 1 (meets the criteria). The total score ranges from 0 to 14, where a score of 9 or higher indicates high adherence to the Mediterranean diet. Higher scores represent greater adherence.
Measured: Baseline and 1-year follow-up
Comorbidity Profile and Disease Burden via ICD-10 Classification
Evaluation of participant medical history and current health status classified according to the International Classification of Diseases, 10th Revision (ICD-10). Diagnoses will be extracted from electronic medical records or clinical interviews and mapped to their corresponding ICD-10 codes. The analysis will focus on the total number of coexisting chronic conditions per participant (disease burden) and the prevalence of major ICD-10 diagnostic chapters (e.g., cardiovascular, metabolic, musculoskeletal diseases).
Measured: Baseline and 1-year follow-up
Hematological and Biochemical Panels
Evaluation of laboratory blood markers prior to baseline to characterize the participants' physiological status. The panels include: 1) Hematology: Hemoglobin, hematocrit, white blood cells, and neutrophils; 2) Glycemic Control: Fasting glucose and HbA1c; 3) Lipid Profile: Total cholesterol, LDL, HDL, and triglycerides; 4) Renal Function: Creatinine, eGFR, and urea; 5) Hepatic Function: AST, ALT, and bilirubin; 6) Inflammation \& Nutrition: C-reactive protein (CRP), albumin, and total proteins; 7) Endocrine \& Bone Metabolism: Vitamin D, TSH, and calcium. All analytes are measured from fasting venous blood samples using automated laboratory assays.
Measured: Baseline and 1-year follow-up
Blood Pressure
Systolic and diastolic blood pressure measured in mmHg. Reported as mean/median descriptive baseline value.
Measured: Baseline
Heart Rate
Heart rate measured in beats per minute (bpm). Reported as mean/median descriptive baseline value.
Measured: Baseline
Oxygen Saturation
Peripheral oxygen saturation measured as percentage (%). Reported as mean/median descriptive baseline value.
Measured: Baseline
Body Temperature
Body temperature measured in degrees Celsius (°C). Reported as mean/median descriptive baseline value.
Measured: Baseline
Body Weight
Body weight measured in kilograms (kg). Reported as mean/median descriptive baseline value.
Measured: Baseline
Height
Height measured in meters (m). Reported as mean/median descriptive baseline value.
Measured: Baseline
Estimated Standing Height
Standing height (cm) estimated using knee height measurement according to the validated Chumlea equations. Knee height is measured as the distance (cm) from the heel (plantar surface) to the anterior surface of the thigh just proximal to the knee (femoral condyle), with the knee and ankle positioned at 90° angles.
Sex-specific equations incorporating age are applied to estimate stature. Measurement Units: Centimeters (cm). This method is validated for populations in whom direct standing height measurement is not feasible (e.g., bedridden, frail, or with postural deformities). Women: Height (cm) = 84.88 + (1.83 × knee height [cm]) - (0.24 × age [years]). Men: Height (cm) = 64.19 + (2.02 × knee height [cm]) - (0.04 × age [years])
Measured: Baseline
Body Mass Index (BMI)
Body mass index calculated as kg/m². Reported as mean/median descriptive baseline value.
Measured: Baseline
Calf circumference
Calf circumference measured in centimeters (cm) at the point of maximum circumference of the calf. Measurements are obtained with the participant in a seated or supine position using a non-stretchable measuring tape.
Method of Assessment: Anthropometric measurement performed using a calibrated measuring tape. The measurement is taken on the non-dominant leg when feasible. Reported as descriptive statistics (mean and standard deviation or median and interquartile range, as appropriate).
Measured: Baseline
Mid-Upper Arm Circumference (MUAC)
Mid-upper arm circumference measured in centimeters (cm) at the midpoint between the acromion and the olecranon process on the upper arm.
Method of Assessment: Anthropometric measurement using a non-stretchable measuring tape. The measurement is performed on the non-dominant arm when feasible, with the arm relaxed. Reported as descriptive statistics (mean and standard deviation or median and interquartile range, as appropriate).
Measured: Baseline
Ocular Screening Findings (Composite Clinical Assessment)
Composite outcome based on clinical ocular screening findings assessed through direct examination. The presence (Yes/No) of the following signs will be recorded for each participant: Eyelid crusting or pus; Excessive ocular discharge; Inverted eyelashes (trichiasis); Abnormal eyelid closure; Scleral redness; Iris opacity and/or redness.
Each component will be assessed as a binary variable (present/absent). The composite outcome may be defined as the presence of ≥1 abnormal finding.
Measurement Units: Categorical (Yes/No) Standardized clinical ocular examination performed by trained healthcare personnel using visual inspection under appropriate lighting conditions.
Individual components will be reported as participant counts and percentages The composite outcome will be reported as the proportion of participants with ≥1 abnormal finding.Total number of abnormalities per participant may be summarized (e.g., mean or median count)
Measured: Baseline
Waist-to-Hip Ratio (WHR)
Waist-to-hip ratio (WHR) calculated as the ratio of waist circumference to hip circumference. Waist circumference is measured (cm) at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest. Hip circumference is measured (cm) at the widest portion of the buttocks.
WHR is used as an indicator of body fat distribution and central (abdominal) obesity. Measurement Units: Unitless ratio (waist circumference [cm] / hip circumference [cm]). Anthropometric measurements performed using a non-stretchable measuring tape. Measurements are taken with the participant standing, with light clothing, and recorded to the nearest 0.1 cm. WHR is calculated using recorded values and is reported as mean and standard deviation or median and interquartile range, as appropriate. May also be categorized using established risk thresholds (e.g., >0.90 in men, >0.85 in women). It is a validated indicator of central adiposity and is associated with cardiometabolic risk.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start4 Feb 2026
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 333 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Fundacion Miguel Servet
- Sponsor type
- University, hospital or other
- Collaborators
- Government of Navarra
- Responsible party
- Sponsor
- Investigators
- Nicolas Martínez Velilla, MD and PhD, Principal investigator, Navarrabiomed, Hospital Universitario de Navarra, IdisNa, Universidad Pública de NavarraChenhui Chen, MD, Study director, Navarrabiomed, Hospital Universitario de Navarra, IdisNa, Universidad Pública de NavarraEnrique Santamaría, PhD, Study chair, Navarrabiomed, Hospital Universitario de Navarra, IdisNa, Universidad Pública de Navarra
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07707297
- Sponsor's protocol ID
- BIOANCIENT
- Acronym
- BIOANCIENT
- Status last verified
- Jul 2026
- First submitted
- 18 Jun 2026
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: We will share individual participation data under specific requests.
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BIOANCIENT: Cohort of Centenarians in Navarra (1926-1927)
- ClinicalTrials.gov ID
- NCT07707297
- Acronym / sponsor ID
- BIOANCIENT / BIOANCIENT
- Conditions
- Aging, Cellular Senescence, Biomarkers / Blood, Age-Related Diseases, Frailty
- Keywords
- Centenarians, Healthy aging, Senescence, Geroscience, Age-related diseases, Longevity, Senescence biomarkers, Personalized medicine
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 333 participants (estimated)
- Lead sponsor
- Fundacion Miguel ServetUniversity, hospital or other
- Collaborators
- Government of Navarra
- Study start
- 4 Feb 2026 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Demographic aging is a growing global challenge, driven by increasing life expectancy and declining birth rates, with projections indicating that more than 30% of the European population will be over 65 years old by 2100. Centenarians represent a unique biological model of extreme longevity, often exhibiting delayed onset of age-related diseases and preserved functional capacity.
This study aims to establish an intergenerational cohort of centenarians in Navarra (Spain) to investigate the biological, clinical, environmental, and lifestyle factors associated with extreme longevity. By integrating multidimensional data-including clinical assessments, functional and cognitive measures, and biological markers-this study seeks to improve understanding of aging mechanisms and identify potential determinants of healthy aging.
Detailed description
Demographic aging is a phenomenon with increasing structural impact, driven by rising life expectancy and declining birth rates. According to projections by Eurostat and the WHO, by 2050 more than 30% of the European population will be over 65 years old, posing significant challenges for the sustainability of healthcare and social systems, and requiring the development of specific strategies that integrate knowledge from geroscience, biotechnology, and artificial intelligence applied to health.
Navarre has privileged conditions for research into healthy aging, given its high rate of centenarians (44.09 per 100,000 inhabitants) and its high-level healthcare and scientific infrastructure. These strengths make the region an ideal environment for designing and implementing innovative strategies aimed at improving the health and quality of life of older adults, contributing to the sustainability of the healthcare system.
Centenarians constitute a particularly valuable biological model, as they reach advanced ages with relatively preserved functionality, suggesting the presence of protective mechanisms that remain incompletely understood. Contemporary geroscience adopts a holistic approach, emphasizing the interaction between genetic factors (such as longevity-associated alleles), epigenetic mechanisms (including DNA methylation), and environmental influences (including diet, physical activity, and living conditions) in shaping aging trajectories.
Multifactorial approaches have been increasingly applied to the study of centenarian cohorts, integrating clinical data with biomarkers of aging. Studies such as the Okinawa Centenarian Study have demonstrated associations between longevity and lifestyle factors including diet, physical activity, and social support, whereas the New England Centenarian Study has highlighted the contribution of genetic factors to extreme longevity and delayed onset of cardiovascular disease. European cohorts have similarly identified favorable metabolic profiles and delayed development of chronic conditions, often with a relevant hereditary component.
The present study aims to integrate multiple domains of knowledge in order to deepen the understanding of the biological mechanisms underlying longevity, reduce diagnostic barriers, optimize therapeutic strategies and healthcare resource utilization, and ultimately improve the quality of life of older adults.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 5 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Centenarians resident in Navarre - Spain | – | –Centenarians (individuals aged ≥100 years) residing in Navarre, Spain. |
Who may qualify
- Ages
- 100 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- The study population consists of very old adults aged 100 years and older residing in Navarre, Spain. Participants will be community-dwelling or institutionalized individuals who meet the inclusion criteria and are able to undergo a comprehensive geriatric assessment. The study aims to include a representative sample of the centenarian population in the region.
Key inclusion criteria (2 listed)
- Individuals aged ≥100 years
- Residents of Navarre, Spain
Key exclusion criteria (2 listed)
- Clinical decompensation within the last month, including hemodynamic instability, acute illness, or hospitalization;
- End-of-life condition, defined as a clinical state of irreversible deterioration with a life expectancy of days to weeks, as determined by a physician.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Integrated biological aging profile based on clinical and multi-omics biomarkers.
Time frame: Baseline and 1-year follow-up
Clinical, funtional and molecular characterization of centenarian individuals using multi-omics biomarkers
37 secondary outcomes
Cognitive Function assessed with Mini Mental State Examination (MMSE)
Time frame: Baseline and 1-year follow-up
Functional status measured with Barthel Index
Time frame: Baseline and 1-year follow-up
Physical function assessed by Short Physical Performance Battery (SPPB)
Time frame: Baseline and 1-year follow-up
Frailty assessed by Fried Frailty Phenotype
Time frame: Baseline and 1-year follow-up
Lawton Instrumental Activities of Daily Living (IADL)
Time frame: Baseline and 1-year follow-up
Nutritional Status assessed using the Mini Nutritional Assessment - Short Form (MNA-SF)
Time frame: Baseline and 1-year follow-up
Hand Grip Strength
Time frame: Baseline and 1-year follow-up
Lower Limb Muscle Strength
Time frame: Baseline and 1-year follow-up
Sarcopenia Risk (SARC-F questionnaire)
Time frame: Baseline and 1-year follow-up
Cognitive Function (Clock Drawing Test)
Time frame: Baseline and 1-year follow-up
Depressive Symptoms (Geriatric Depression Scale - GDS-15)
Time frame: Baseline and 1-year follow-up
Health-Related Quality of Life (EQ-5D-5L)
Time frame: Baseline and 1-year follow-up
Life Satisfaction (Satisfaction With Life Scale - SWLS)
Time frame: Baseline and 1-year follow-up
Comorbidity Burden
Time frame: Baseline and 1-year follow-up
Proteomic Biomarkers
Time frame: Baseline (single assessment)
Mobility and Functional Performance (Timed Up and Go Test - TUG)
Time frame: Baseline and 1-year follow-up
Polypharmacy
Time frame: Baseline and 1-year follow-up
Bioimpedance Analysis (BIVA - Bioelectrical Impedance Vector Analysis)
Time frame: Baseline and 1-year follow-up
Falls (Number of falls over the past 12 months)
Time frame: Baseline and 1-year follow-up
Fear of Falling
Time frame: Baseline and 1-year follow-up
Pain Intensity
Time frame: Baseline and 1-year follow-up
Shoulder Mobility (External Rotation and Abduction and; Internal Rotation and Adduction)
Time frame: Baseline and 1-year follow-up
Adherence to the Mediterranean Diet Measured by the MEDAS Score
Time frame: Baseline and 1-year follow-up
Comorbidity Profile and Disease Burden via ICD-10 Classification
Time frame: Baseline and 1-year follow-up
Hematological and Biochemical Panels
Time frame: Baseline and 1-year follow-up
Blood Pressure
Time frame: Baseline
Heart Rate
Time frame: Baseline
Oxygen Saturation
Time frame: Baseline
Body Temperature
Time frame: Baseline
Body Weight
Time frame: Baseline
Height
Time frame: Baseline
Estimated Standing Height
Time frame: Baseline
Body Mass Index (BMI)
Time frame: Baseline
Calf circumference
Time frame: Baseline
Mid-Upper Arm Circumference (MUAC)
Time frame: Baseline
Ocular Screening Findings (Composite Clinical Assessment)
Time frame: Baseline
Waist-to-Hip Ratio (WHR)
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- Information about the projectLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided. We will share individual participation data under specific requests.
Related trials for Aging
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nicolas Martínez Velilla, MD and PhD principal investigator
Navarrabiomed, Hospital Universitario de Navarra, IdisNa, Universidad Pública de Navarra
Chenhui Chen, MD study director
Navarrabiomed, Hospital Universitario de Navarra, IdisNa, Universidad Pública de Navarra
Enrique Santamaría, PhD study chair
Navarrabiomed, Hospital Universitario de Navarra, IdisNa, Universidad Pública de Navarra
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aging and Cellular Senescence, run by Fundacion Miguel Servet at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nicolás Martínez Velilla, MD and PhD (+34 848 422 287, nicolas.martinez.velilla@navarra.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Integrated biological aging profile based on clinical and multi-omics biomarkers. (time frame: Baseline and 1-year follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.